FDA warns about a risk of blood cancer in TNF blockers

04/14/2011 | Reuters

The FDA cautioned that a drug class called tumor necrosis factor inhibitors has been associated with hepatosplenic T-cell lymphoma, particularly among teens and young adults. A majority of the cases involved patients treated for ulcerative colitis or Crohn's disease. Labels have been updated for Johnson & Johnson's Remicade and Abbott Laboratories' Humira, the FDA said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA